ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analyzing the safety, efficacy and biomedical relevance of new compounds, today announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

ZeClinics supports academic, pharmaceutical and biotech organizations in pre-clinical studies by providing services based on its zebrafish disease models. The Company is applying CRISPR/Cas9 technology to create single knock-out, double knock-out and somatic F0 knock-out zebrafish variants.

CRISPR/Cas9 has become an important tool in many areas of research. At ERS we are expanding our efforts to make the technology broadly available, so it can be used by as many people as possible, and we are therefore pleased to support ZeClinics with this license agreement. By providing them access to this foundational CRISPR/Cas9 intellectual property, ZeClinics is able to continue to provide valuable preclinical models and services for drug discovery and development.”

Eric Rhodes, CEO, ERS Genomics

The zebrafish model is a powerful tool for answering complex questions. The use of CRISPR tools to modify zebrafish models allows us to streamline functional genomic processes, provide insights into biologically relevant knowledge on diseases. The license from ERS expands our CRISPR IP portfolio and, alongside the license from The Broad Institute, allows us to push ahead with the application of this advanced technology, ultimately increasing the validity and potency of zebrafish models for the drug discovery process.”

Simone Calzolari, CEO and Co-founder, ZeClinics

Financial details of the agreement are not disclosed.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ZeClinics SL. (2021, February 16). ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement. News-Medical. Retrieved on May 18, 2024 from https://www.news-medical.net/news/20210216/ERS-Genomics-and-ZeClinics-sign-CRISPRCas9-license-agreement.aspx.

  • MLA

    ZeClinics SL. "ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement". News-Medical. 18 May 2024. <https://www.news-medical.net/news/20210216/ERS-Genomics-and-ZeClinics-sign-CRISPRCas9-license-agreement.aspx>.

  • Chicago

    ZeClinics SL. "ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement". News-Medical. https://www.news-medical.net/news/20210216/ERS-Genomics-and-ZeClinics-sign-CRISPRCas9-license-agreement.aspx. (accessed May 18, 2024).

  • Harvard

    ZeClinics SL. 2021. ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement. News-Medical, viewed 18 May 2024, https://www.news-medical.net/news/20210216/ERS-Genomics-and-ZeClinics-sign-CRISPRCas9-license-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.